Also like this

Peer chemical accounts with a similar energy profile — reference on calls.

Chemical

Haridwar · Chemical / Process

ChemicalHaridwarUPCLCaptive power

SRF Limited 9/10

Kashipur · Chemical / Process

ChemicalUPCLCaptive powerISO 50001

Emami Limited 8/10

Pantnagar · Chemical / Process

ChemicalUPCLCaptive powerISO 50001

Henkel Adhesive Technologies India Pvt Ltd 8/10

Pantnagar · Chemical / Process

ChemicalUPCLCaptive powerISO 50001

Axa Parenterals Ltd

Fit 8/10 Band A Haridwar UPCL ISO 50001 ✓ Chemical

Why Band A

This is a **sterile parenteral** plant (not bulk chemical) — continuous cleanroom HVAC, WFI/PW, sterilizers at ~108°C, compressors and BFS lines create a classic high base-load + MD-spike utility profile. Heilsa ramp (vials / PFS / ampoules) means new loads stacking on the same UPCL bill while baselines are still settling. Decision is plant-led; a General Manager intro is the strongest door we have in this campaign.

Bill & utility

Bill band: ₹230 Cr**, with FY26 group revenue expected around **₹270–300 Cr**
DISCOM: UPCL
Energy mgmt: ISO 50001 ✓

Champion & entry angle

General Manager (plant) General Manager — Plant / Operations

Email LinkedIn

Lead with: **attribute MD and monthly bill leakage to specific sterile-utility events (HVAC vs sterilizer vs compressor vs BFS campaign overlap) and verify the correction on the next UPCL bill — especially while Heilsa injectables are still ramping.**

Fit score **8/10** matches prior lead research — held back from 9–10 by (a) revenue still ~₹230 Cr vs ICP sweet spot ₹300 Cr+, (b) **unverified** monthly electricity bill vs ≥ ₹30L gate.

Open with ≈45 sec

Sir, Utso Sarkar — co-founder of Stamped Energy, IIT Roorkee. [Friend] mentioned you run the plant at Axa. 40 seconds?

Proof

Early sterile/process sites saw 15–20% off within weeks. No hardware, no DCS writes.

Ask

Could we take one feeder for a 90-day, evidence-verified look? Just 20 minutes to see if the bill band fits.

Email subject: One UPCL line item we can verify in 90 days — Roorkee sterile utilities

Discovery questions pick 2–3

Confirm the General Manager's full name, plant (Axa vs Heilsa), and work WhatsApp/email with the introducer before any CRM entry.
On first call, ask monthly UPCL bill band and number of HT connections — hard gate for Band A pricing.
Ask which hurts more this quarter: MD peaks, sterilizer steam/electric overlap, or HVAC between campaigns.
Use Heilsa ramp as timing hook: "Now that vials/PFS are commercial, is the utility baseline settled or is the bill still moving with mix?"

Watch out

Top flag: Monthly electricity bill and sanctioned MD are unverified; revenue is below classic Band A ₹300 Cr floor though FY26 guide approaches it.

Don't lead with: Do not lead with dashboards, AI, or carbon; lead with ₹ on the bill.

Deep research dossier

Full dossier Call prep

Axa Parenterals Ltd

Stamped-relevant intel for pre-outreach due diligence on Axa Parenterals Roorkee sterile parentals campus and Heilsa subsidiary ramp.

8/10 ICP fit

UPCL DISCOM

ISO 50001 ✓ Energy mgmt

Haridwar Plant

Chemical Uttarakhand

₹

Bill band

₹230 Cr**, with FY26 group revenue expected around **₹270–300 Cr**

→

Entry angle

**attribute MD and monthly bill leakage to specific sterile-utility events (HVAC vs sterilizer vs compressor vs BFS campaign overlap) and verify the correction on the next UPCL bill — especially while Heilsa injectables are still ramping.**

Top flag

Monthly electricity bill and sanctioned MD are unverified; revenue is below classic Band A ₹300 Cr floor though FY26 guide approaches it.

Primary champion General Manager (plant) General Manager — Plant / Operations

Email LinkedIn Outreach scripts →

1. Company overview & snapshot

Axa Parenterals Limited is a Roorkee (Uttarakhand)-based private pharmaceutical manufacturer of sterile parenteral preparations — intravenous fluids, large and small volume parenterals, ophthalmic and nasal drops, respules, and injectables — plus contract manufacturing for other brands. It was incorporated in 2005 by Krishan Kumar. The public brand story (Accuracy, Excellence, Assurance) and WHO-GMP / PIC/S positioning are aimed at domestic hospital supply and regulated-market export; Bioaxa positions the critical-care specialty arm, and Heilsa Life Sciences Pvt Ltd is the 100% subsidiary for vials, ampoules, emulsions/liposomal lines, lyophilized products, and pre-filled syringes.

Scale is mid-market but growing: CRISIL (Nov 2025) cites FY25 consolidated-relevant operating income of about ₹230 Cr, with FY26 group revenue expected around ₹270–300 Cr. Networth is estimated near ₹179 Cr (FY25) with low gearing. Export reach is cited at 61+ countries, with export mix rising toward 40–50% of sales as accreditations broaden. IndiaMart and company materials describe ~1.45 lakh sq.ft land and ~2.8 lakh sq.ft built area; capacity claims include ~50M LVP bottles/year and ~50M SVP vials/year, with four BFS machines (Rommelag / Weiler).

Timing for Stamped: major Heilsa capex is described as commercialized by Dec 2024 without large overruns; FY26 focus is ramp of premium injectables (paracetamol, propofol, enoxaparin, heparin, etc.) targeting ₹30–40 Cr from the new segment in FY26 and ₹80–100 Cr medium term. That is exactly when plant leadership cares about utility cost per batch and MD on a rising load — not another dashboard project.

Ownership is promoter-led (Ruchir Gupta, Sumit Kumar Agarwal, Yasha Agarwal among whole-time directors). Registered office is Netaji Subhash Place, Delhi; manufacturing is Roorkee/Haridwar belt. LinkedIn company page shows ~180 people and lists operations leadership including VP Operations Pravir Saxena (from May 2025) and EVP Dr. Sanjay Mohan Shrivastava.

2. Energy profile

Roorkee / Haridwar industrial loads are typically on UPCL (Uttarakhand Power Corporation Ltd). Exact sanctioned demand, tariff category, and monthly HT bill are not public — treat the Band A electricity gate (≥ ₹30 lakh/month) as verify-on-first-call.

Energy intensity for sterile parentals is structurally high even at ~₹230 Cr revenue: 24/7 cleanroom HVAC, purified water / WFI loops, compressed air, cold chain / HVAC for critical care, and terminal sterilization (company materials cite superheated sterilizers at ~108°C after aseptic BFS fill). Steam for sterilization and process heating is almost certain; a Steamax case study about a Roorkee pharma FO→biomass boiler retrofit (₹12L → ₹6.9L/month fuel) is not confirmed as Axa — use only as regional proof that thermal fuel cost is a live management topic in this belt.

Known likely bill pains: (1) MD spikes when BFS campaigns, sterilizer cycles, and HVAC restarts overlap; (2) idle hold / between-batch HVAC that stays at production setpoints; (3) Heilsa ramp stacking vial/PFS/ampoule utilities on the same or adjacent feeders without a settled baseline; (4) PF / demand-charge hygiene if metering is plant-total rather than utility-block. ISO 50001 / PAT / BRSR were not confirmed on public pages — do not lead with EnMS language unless they volunteer it.

Bill band working assumption for outreach: likely ₹15–40L+/month HT [~] depending on how many HT connections and whether Heilsa is metered separately — confirm before quoting Band A commercial.

3. Operations, equipment & digital stack

Core process is Blow-Fill-Seal (BFS) aseptic filling: containers blown, filled, and sealed in closed circuit with no human touch, then sterilized. Public materials: four Form-Fill-Seal machines (Rommelag Germany / Weiler USA) — two for LVP, two for SVP — plus dedicated lines claimed for LVP, SVP, ampoules, vials, PFS, eyedrops, and respules across the group. Heilsa adds robotic PFS capability positioned for EU-guideline markets.

Utility blocks that matter for Stamped: HVAC AHUs for classified areas, chillers, boilers/steam, sterilizers, compressors, WFI/PW generation and distribution, purified-water loops, effluent treatment, and packaging/secondary. Shift pattern is almost certainly multi-shift / campaign-driven rather than pure continuous chemical.

Digital stack is not publicly named. WHO-GMP / PIC/S and USFDA/EU-oriented design imply batch records, environmental monitoring, and likely PLC/SCADA on filling and utilities — but treat EMS vendor as unknown. Pitch: read-only on existing meters + bill, not “install our sensors” or “replace SCADA.”

4. Stamped Energy fit analysis

Band A rationale: North India process manufacturing, plant-level decision, sterile utilities energy intensity, growth/ramp timing, and a warm General Manager path. Fit score 8/10 matches prior lead research — held back from 9–10 by (a) revenue still ~₹230 Cr vs ICP sweet spot ₹300 Cr+, (b) unverified monthly electricity bill vs ≥ ₹30L gate.

The strongest wedge is: attribute MD and monthly bill leakage to specific sterile-utility events (HVAC vs sterilizer vs compressor vs BFS campaign overlap) and verify the correction on the next UPCL bill — especially while Heilsa injectables are still ramping.

Objection landscape: internal engineering already “watches” utilities; quality will fear any system that touches validated equipment; someone may pitch solar or boiler fuel switch as the only energy project. Stamped positioning: software decision layer, read-only, no PLC writes, WhatsApp-assigned ₹ actions, 90-day kill criteria. Proof that lands for a GM: plant P&L, one verified bill line, zero hardware, founder time from IIT Roorkee — not ESG theatre.

Commercial entry: 60-Day Bill Verification Program on one feeder / one utility block. If bill is ₹10–25L/month, drop to Path B language (meter + bill first) rather than full Band A pricing narrative.

5. Before you reach out

Confirm the General Manager’s full name, plant (Axa vs Heilsa), and work WhatsApp/email with the introducer before any CRM entry.
On first call, ask monthly UPCL bill band and number of HT connections — hard gate for Band A pricing.
Ask which hurts more this quarter: MD peaks, sterilizer steam/electric overlap, or HVAC between campaigns.
Use Heilsa ramp as timing hook: “Now that vials/PFS are commercial, is the utility baseline settled or is the bill still moving with mix?”
Do not call them a chemical plant in conversation — they are sterile pharma / parentals; process analogy is fine, industry label is not.
Do not lead with dashboards, AI, or carbon; lead with ₹ on the bill.
Keep quality comfort explicit: read-only, no control writes, no change to validated recipes.
Prefer GM → Engineering (Mohanakrishnan) path over corporate sales inboxes.

6. Risks, flags & sources

Data quality flags:

Monthly electricity bill and sanctioned MD are unverified; revenue is below classic Band A ₹300 Cr floor though FY26 guide approaches it.
SIDCUL Haridwar Plot 34 vs Roorkee Kishanpur — confirm which site the GM owns and which DISCOM meter is in scope.
Steamax Roorkee FO→biomass case is regional, not proven Axa-specific.
Primary champion legal name depends on personal intro; LinkedIn GM match not locked in this research pass.
“Chemical plant” in casual speech is incorrect for messaging — use sterile / parenteral / injectable.

Sources consulted:

Fit 8/10 Band A Chemical / Process · Uttarakhand

Axa Parenterals Ltd

Haridwar

Primary champion

General Manager (plant)

General Manager — Plant / Operations

Email LinkedIn

Axa Parenterals Limited — Roorkee

Fit score: 8/10 · Chemical / Process Band A · leads/uttarakhand/lead-research-axa-parenterals-2026-07.md

1. Company


Website	https://www.axaparenterals.com
Company LinkedIn	https://in.linkedin.com/company/axa-parenterals-ltd
Plant	AXA House, Kishanpur–Jamalpur, Puhana Chowk, Roorkee–Saharanpur Highway, Roorkee 247667, Haridwar, Uttarakhand (primary); SIDCUL Plot No. 34, Sector 8A, IIE SIDCUL, Haridwar 249403 (listed in prior lead research — confirm role)
Plant phone	+91-7060067001 (CPHI — likely) · +91-9258237506 / +91-9997502111 (Bioaxa — likely) · LinkedIn lists +91-7455804041
Scale	Private; FY25 operating income ~₹230 Cr (CRISIL); group guide ₹270–300 Cr FY26. ~180 LinkedIn headcount. Sterile IV fluids / LVP+SVP / ophthalmics / respules / injectables; 4× Rommelag BFS; Heilsa Life Sciences (100% sub) vials/ampoules/PFS ramp. Export 61+ countries. Clients include majors (Cipla, Biocon, Abbott cited in prior research `[~]`).

Why they fit: This is a sterile parenteral plant (not bulk chemical) — continuous cleanroom HVAC, WFI/PW, sterilizers at ~108°C, compressors and BFS lines create a classic high base-load + MD-spike utility profile. Heilsa ramp (vials / PFS / ampoules) means new loads stacking on the same UPCL bill while baselines are still settling. Decision is plant-led; a General Manager intro is the strongest door we have in this campaign.

2. Who to contact

Primary champion (contact first) — plant P&L · warm intro

General Manager (plant) — General Manager — Plant / Operations (warm intro via personal network — insert legal name before CRM / send)
LinkedIn: https://in.linkedin.com/company/axa-parenterals-ltd
Email: Sales.domestic@axapar.com (verified — Bioaxa; use only until GM work email from introducer) · fallback axapar@axapar.com (verified — company LinkedIn)

Secondary contacts (links/names only — no outreach credits used)

Mohanakrishnan R — Sr. Manager, Projects & Engineering (SVP/LVP) · https://www.linkedin.com/in/mohanakrishnan-r-187493a0
Pravir Saxena — Vice President Operations (from May 2025) · https://www.linkedin.com/in/pravir-saxena-04916ba1
Ruchir Gupta — Whole-Time Director · https://www.linkedin.com/in/ruchir-gupta-91353362
Dr. Sanjay Mohan Shrivastava — Executive Vice President
Verified generic inbox: Sales.domestic@axapar.com · Sales.international@axapar.com

3. Curated email — to GM (short, plant P&L · after warm WhatsApp)

Subject: One UPCL line item we can verify in 90 days — Roorkee sterile utilities

Sir,

I’m Utso Sarkar, co-founder of Stamped Energy (IIT Roorkee energy-systems researchers). We’re a software-only layer on your existing meters/SCADA — read-only — that turns sterile-utility data into specific ₹ actions (which HVAC / sterilizer / compressor event drove MD) and proves the saving on the next UPCL bill.

With four Rommelag BFS lines plus Heilsa injectables ramping, cleanroom and sterilization loads rarely show up as one neat “waste” line — they show up as bill leakage. Early plants saw 15–20% bill cuts within weeks.

If useful, happy to scope a 90-day, one-feeder Bill Verification look — 20 minutes is enough to decide if the bill band fits.

Utso Sarkar · Co-founder, Stamped Energy · stamped.work

4. WhatsApp / LinkedIn DM (warm intro — send this first)

Sir — [Friend’s name] suggested I reach you. I’m with Stamped Energy (IIT Roorkee). We help sterile plants cut the electricity bill by finding which utility event actually drove the UPCL MD/charge — then verifying the saving on the next bill. No new hardware, nothing written to your control system. Would a short call this week be okay? Happy to keep it to 15 minutes.

5. Cold-call script (≈45 seconds)

Open: “Sir, Utso Sarkar — co-founder of Stamped Energy, IIT Roorkee. [Friend] mentioned you run the plant at Axa. 40 seconds?”
Hook: “Four Rommelag BFS lines plus cleanroom HVAC — we sit read-only on your meters, put a rupee number on which utility event drove the MD spike, and verify it on the next UPCL bill.”
Proof: “Early sterile/process sites saw 15–20% off within weeks. No hardware, no DCS writes.”
Ask: “Could we take one feeder for a 90-day, evidence-verified look? Just 20 minutes to see if the bill band fits.”
If busy: “WhatsApp or email OK?”